Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Form 8-K Current Report on July 2, 2020, regarding an event dated July 1, 2020. The Company is an emerging growth company with its common stock listed on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a new financing agreement.
Material Changes
On July 1, 2020, the Company entered into an At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC. Under this agreement, Cocrystal Pharma may issue and sell up to $10,000,000 of its common stock over time. Sales may be conducted via various methods permitted by law, including direct sales on The Nasdaq Capital Market or through negotiated transactions. Wainwright will receive compensation of 3.0% of the gross proceeds from any shares sold under the agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The document notes that the agreement includes customary representations, warranties, and covenants, which were made solely for the benefit of the parties and should not be relied upon as characterizations of the Company's actual condition. It explicitly states that this report does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the full text of the At-The-Market Offering Agreement filed as Exhibit 1.1.
- Review the effective Registration Statement on Form S-3 (File No. 333-237738) and the accompanying prospectus supplement filed on July 1, 2020.
- Monitor future filings for actual sales volumes and proceeds generated under the $10,000,000 cap.
- Confirm the impact of the 3.0% commission on net proceeds should sales occur.